Innovation at the point-of-care

Lumos develops, manufactures and distributes world-leading diagnostic technologies - delivering actionable information, in real time, at the point-of-care.

Welcome to Lumos

World-class point-of-care products

Lumos Diagnostics specializes in rapid, cost-effective and complete point-of-care diagnostic test solutions to help healthcare professionals more accurately assess, diagnose and manage medical conditions.

FebriDx®

Rapid point-of-care test that uses a fingerstick blood sample to aid in the differentiation between bacterial infection and non-bacterial etiology.

ViraDx

Rapid point-of-care test that simultaneously tests for acute respiratory infections caused by the COVID-19, Influenza A and Influenza B viruses.

Lumos Development & Contract Manufacturing Services

Lumos specializes in rapid, cost-effective and complete point-of-care diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions. We offer customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms.

How Lumos can help your business

Strategic Innovation

Initial evaluation of a point-of-care diagnostic test product concept and the development of new diagnostic test assay.

Development and Manufacturing Transfer

Development of new point-of-care diagnostic test products, including use of Lumos technology platform and the customization and integration of Lumos digital reader technology when requested by Lumos clients.

Validation and Commercial Manufacturing

Clinical and product validation and commercial-scale manufacture of test strips and readers.

Medical, Quality and Regulatory Affairs

In house, qualified team to support all stages of product development and commercialization.

"The last three years has been a truly transformative chapter for point-of-care diagnostics, which our team has navigated with care and conviction. We have emerged with two products on market in the US, and a suite of custom services for the healthcare industry, which we are strategically delivering in key global markets."

Doug Ward | Lumos CEO and Managing Director

Lumos News

Lumos and BARDA to Partner to Support FebriDx® CLIA Waiver Study and Application
3 October 2024

Lumos has been awarded US$2,984,571 from the Biomedical Advanced Research and Development Authority (BARDA)...

Lumos Awarded National Contract with MediGroup for FebriDx®
25 September 2024

Lumos Diagnostics has been awarded placement of their novel POC test, FebriDx®...

Lumos Appoints Thermo Fisher Scientific as US Distributor for FebriDx®
16 September 2024

Lumos Diagnostics has signed an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific...

Subscribe for Lumos news and investor updates

By entering your email address you are agreeing to our Privacy Policy.